Emergent BioSolutions Inc. (NYSE: EBS) has recently secured a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply Cyfendus® (anthrax vaccine adsorbed, adjuvanted). This modification follows a previous contract modification of $50 million announced in December 2024. Cyfendus® is a two-dose anthrax vaccine for post-exposure prophylaxis use, and the deliveries are expected to commence this calendar year and be completed by March 2026.
The company's senior vice president, Paul Williams, emphasized the significance of this contract in supporting the U.S. government's efforts to safeguard civilian populations against the potential threat of anthrax. This is in line with Emergent's commitment to leveraging a U.S.-based supply chain for anthrax vaccines to support the nation's national security priorities.
The Cyfendus® vaccine was approved by the U.S. Food and Drug Administration in July 2023 for individuals 18 through 65 years of age when given with recommended antibacterial drugs. Anthrax is considered a tier 1 biological threat due to its potential for use in bioterrorist incidents and its implications for public health and national security.
It's important to note that the contract modification has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract HHSD100201600030C.
The press release also provided important safety information related to the use of Cyfendus® and urged reporting of any suspected adverse reactions to the vaccine.
The market has reacted to these announcements by moving the company's shares -0.66% to a price of $7.58. For the full picture, make sure to review Emergent BioSolutions's 8-K report.
